Experience with tenofovir disoproxil fumarate for antiretroviral therapy

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 7, 2008, Pages 1197-1209

  Stephan, Christoph ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Efficacy; Hepatitis B; Renal safety; Safety; Switch studies; Tenofovir; Viread

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ADEFOVIR; ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; ATAZANAVIR; CIDOFOVIR; CREATININE; DIDANOSINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EFAVIRENZ PLUS LAMIVUDINE PLUS STAVUDINE; EFAVIRENZ PLUS LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FORCAVIR; FOSCARNET; GANCICLOVIR; LAMIVUDINE; PLACEBO; RIBAVIRIN; RITONAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; VALGANCICLOVIR; VIDEX EC; ZIDOVUDINE; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE;

ACUTE KIDNEY FAILURE; AGE; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BONE DENSITY; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIZZINESS; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FANCONI RENOTUBULAR SYNDROME; FOOD; FOOD DRUG INTERACTION; FRACTURE; GASTROINTESTINAL DISEASE; GENDER; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPOPHOSPHATEMIA; KIDNEY DISEASE; LACTIC ACIDOSIS; LIPODYSTROPHY; LYMPHOCYTE COUNT; MITOCHONDRIAL TOXICITY; MONOTHERAPY; NEPHROTOXICITY; NEURITIS; PANCREATITIS; PATHOLOGIC FRACTURE; PATIENT MONITORING; PERIPHERAL NEUROPATHY; SIDE EFFECT; WEIGHT GAIN; ADULT; ANTIVIRAL RESISTANCE; CHILD; DRUG COMBINATION; DRUG INTERACTION; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; CHILD; DRUG INTERACTIONS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; PHOSPHONIC ACIDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 43049173642     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.7.1197     Document Type: Article

References (70)

1. European Medicines Evaluation Agency (EMEA). Tenofovir disoproxil (Viread). 5 February 2002. Available from: http://www.emea.europa.eu/ humandocs/PDFs/EPAR/viread/H-419-PI-en.pdf [Last accessed 14 December 2007]
2. Hawkins T, Veikley W, St Claire R, et al. Intracellular pharmacokinetics of tenofovir-DP and carbovir-TP in patients receiving triple nucleoside regimens [abstract 2.4]. 5th International Workshop on Clinical Pharmacology of HIV Therapy; Rome; 2004
3. Kearney BP, Gill SC, Flaherty JF, et al. Effect of demographic variables on the pharmacokinetics of tenofovir DF in HIV-infected patients and healthy subjects [abstract 504]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago; 2001
4. Kearney BP, Isaacson E, Sayre J, et al. Didanosine and tenofovir DF drug-drug interaction: assessment of didanosine dose reduction [abstract 533]. 10th Conference on Retroviruses and Opportunisitic Infections; Boston; 2003
5. Karrer U, Ledergerber B, Furrer H, et al. Dose-dependent influence of didanosine on immune recovery in HIV-inficced patients treated with tenofavir. AIDS 2005;19:1987-94
6. Blanchard JN, Wohlfeiler M, Canas A, et al. Pancreatitis with didanosine and tenofovir disoproxil fumarate [corrected]. Clin Infect Dis 2003;37:e57-62
7. Pellegrin I, Breilh D, Ragnaud JM, et al. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study). Antivir Ther 2006;11:421-9
8. Le Tiec C, Barrail A, Goujard C, Taburet AM. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin Pharmacokinet 2005;44:1035-50
9. Johnson M, Grinsztejn B, Rodriguez C, et al. Arazanavit plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005;19:685-94
10. Taburet AM, Piketty C, Chazallon C, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004;48(6):2091-6
11. Kaul S, Bassi K, Damle B, et al. Pharmacokinetic (PK) evaluation of the combination of atazanavir (ATV), enteric coated didanosine (ddI-EC), and tenofovir disoproxil fumarate (TDF) for a once-daily antiretroviral regimen. [abstrac A-1616]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago; 2003
12. Gallant JE, Rodriguez AE, Weinberg WG, et al. ESS30009: early virologic non-response to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive patients. J Infect Dis 2005;192:1921-30
13. Maitland D, Moyle G, Hand J, et al. Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial. AIDS 2005;19:1183-8
14. Gallant JE, Stasziewski S, Pozniak AL, et al. For the 903 Study Group. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naive patents: a randomized trial. JAMA 2004;292:191-201
15. Cassetti I, Madruga JV, Muhamed AH, et al. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naïve HIV-1-infected patients. HIV Clin Trials 2007;8:164-72
16. Arribas J, Pozniak AI, Gallant JE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquit Immune Defic Syndr 2008; In press
17. Squires K, Pozniak AL, Pierone G Jr, et al. For the 907 study team. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med 2003;139:313-20
18. Fux CA, Simcock M, Wolbers M, et al. Tenofovir treatment is associated with a decrease in calculated glomendar filtration rates in a large observational cohort. 14th Conference on Retroviruses and Opportunistic Infections [poster abstract 834]. Los Angeles; 2007
19. Peyrière H, Reynes J, Rouaner I, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquit Immune Defic Syndr Hum Retrovirol 2004;35:269-73
20. Fisher EJ, Chaloner K, Cohn DL, et al. The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial. AIDS 2001;15:1695-700
21. Vandercam B, Moreau M, Goffin E, et al. Cidofovir-induced end-stage renal failure. Clin Infect Dis 1999;29:948-9
22. Ray AS, Vela JE, Robinson KL, et al. Efflux of tenofovir by the multidrug resistance-associated protein 4 (MRP4) is not affected by HIV protease inhibitors [abstract PE4.3/13]. In: Program and abstracts of the 10th European AIDS Conference; Dublin; 2005
23. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41
24. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70
25. Izzedine H, Isnard-Bagnis C, Hulot J-S, et al. Renal safety of tenofovir in HIV treatment-experienced patients. AIDS 2004;18:1074-6
26. Parish MA, Gallant JE, Moore R. Changes in renal function in patients treated with tenofovir DF (TDF) vs. nucleoside reverse transcriptase inhibitors [abstract 751]. 11th Conference on Retroviruses and Opportunisitic Infections; San Francisco; 2004
27. Gallant JE, Staszewski S, Pozniak AL, et al. Renal safety profile of tenofovir DF (TDF)-containing compared to non-TDF-containing regimens through 144 weeks in antiretroviral-naive patients [abstract P9./7/05]. 11th European AIDS Conference; 2007 October 24-27; Madrid, Spain
28. Jones R, Stebbing J, Nelson M, et al. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study. J Acquit Immune Defic Syndr Hum Retrovirol 2004;37:1489-95
29. Gallant JE, Parish KA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005;40:1194-8
30. Nelson M, Cooper D, Schooley R, et al. The safety of TDF for the treatment of HIV infection: the first 4 years [poster abstract 781]. 13th Conference on Retroviruses and Opportunistic Infections; Denver, 2006
31. Bagnis C. Assessment of drug-induced nephrotoxicity in HIV patients. Ninth International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; 2007 July 19-21; Sydney. Plenary lecture. Available from: http://www.intmedpress.com/lipodystrophy/ default.cfm?itemtypeid=15&title=Webcasts#Thursday_19_July_2007 [Last accessed 14 December 2007]
32. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006;354:251-60. Available from: http://content.nejm.org/cgi/ conten/abstract/354/3/251 [Last accessed 14 December 2007]
33. Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005;40:1559-85
34. Sax PE, Gallant JE, Klotman PE. Renal safety of tenofovir disoproxil fumarate. AIDS Reader 2007;17:90-2,99
35. Fisher M, Moyle G, Ebrahimi R; the SWEET study group. Switching from Combivir (CBV, AZT/3TC) to truvada (TVD, TDF/FTC) maintains vital suppression, prevents and reverses limb fat loss, and improves biochemical parameters: results of a 48 week randomised study (abstract PS5/7]. 11th European AIDS Conference; Madrid; 2007
36. Moyle G, Fisher M; the SWEET DEXA Sub-study Group. Factors associated with low limb fat in a cohort of zidovudine-treated subjects [poster abstract P12]. 9th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; Sydney; 2007
37. Martinez E, Arranz JA, Podzamczer D, et al. Efficacy and safety of NRTI's switch to tenofovir plus emtricitabine vs. abacavir plus lamivudine in patients with virologic suppression receiving lamivudine containing HAART: the BICOMBO study [abstract WESS102]. 4th International AIDS Society Conference on HIV Treatment and Pathogenesis; Sydney; 2007
38. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B 5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002;359:722-3
39. Martin A, Smith D, Carr A, et al. for the Mitochondrial Toxicity (MITOX) Study Group. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 2004;18:1029-36
40. Margot NA, Lu B, Cheng A, et al. Resistance development over 144 weeks in treatment-naïve patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903. HIV Med 2006;7:442-50
41. McColl DJ, Margot NA, Wulfsohn M, et al. Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate. J Acquit Immune Defic Syndr 2004;37:1340-50
42. McColl DJ, Miller MD. The use of tenofovir disoproxil fumarate for the treatment of nucleoside-resistant HIV-1. J Antimicrob Chemother 2003;51:219-23
43. Parikh UM, Bamas DC, Faruki H, Mellors JW. Antagonism between the HIV-1 reverse-transcriptase mutation K65R and thymidine-analogue mutations at the genomic level. J Infect Dis 2006;194:651-6
44. Miller M, Zhong L, Chen S, et al. Multivariate analyses of antiviral response to tenofovir DF therapy in antiretroviral-experienced patients. Antivir Ther 2002;7:16
45. White KL, Chen JM, Feng JY, et al. The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations. Antivir Ther 2006;11(2):155-63
46. Staszewski S, Dauer B, Stuermer M, et al. Intensification of a failing regimen with AZT may cause sustained virologic suppression in the presence of the K65R mutation [abstract 89, poster 9.34]. Third European HIV Drug Resistance Workshop; Athens; 2005
47. deRuiter A, Pozniak AL, Staszewski S, et al. Long-term safety and efficacy of tenofovir DF versus stavudine in combination with lamivudine and efavirenz in antiretroviral-naïve women: 144 week results [abstract MoOrB1083]. 15th International AIDS Conference; Bangkok; 2004
48. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services. 2007:1-143. Available from: http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf [Last accessed 14 December 2007]
49. Haberl A, Linde R, Faul-Burbes C, et al. Effective MTCT-prophylaxis with AZT, TDF plus FTC or 3TC [poster abstract PE14.2/3]. 10th European AIDS Conference; Dublin; 2005
50. European AIDS Clinical Society (EACS). European guidelines for the management and treatment of HIV infected adults in Europe 2007. Available from: http://www.eacs.eu/guide/index.htm [Last accessed 14 December 2007]
51. US Food and Drug Administration. Viread® US label. 25 June 2004. Available from: http://www.gileadhiv.com/320Viread.aspx [Last accessed 14 December 2007]
52. Ramos JT, Gonzales-Tme MI, Rojo P, et al. Experience with tenofovir disoproxil fumarate (TDF) in heavily pretreated HIV-infected children [abstract TuPeB4465]. 15th International AIDS Conference; Bangkok; 2004
53. Saag M, Cahn P, Raffi F, et al. For the FTC 301 A Study Team. Efficacy and safety of emtricitabine vs. stavudine in combination therapy in antiretroviral-naïve patients: a randomized trial. JAMA 2004;292:180-90
54. British HIV Association. Treatment of HIV-infected adults with antiretroviral therapy. 2006. Available from: http://www.bhiva.org/ cms1191541.asp [Last accessed 14 December 2007]
55. European Medicines Evaluation Agency (EMEA). Committee for Medicinal Products for Human Use. Summary of positive opinion for Atripla. 18 October 2007. Available from: http://www.emea.europa.eu/pdfs/human/ opinion/atripla_25587607en.pdf [Last accessed 14 December 2007]
56. European Centre for Disease Prevention and Control. Annual epidemiological report on communicable diseases in Europe 2005 (published in December 2007). Available from: http://www.ecdc.europa.eu/ pdf/ECDC_epi_report_2007.pdf [last accessed 27 December 2007]
57. Thio CL, Sulkowski MS, Thomas DL. Treatment of chronic hepatitis B in HIV-infected persons: thinking outside the black box. CID 2005;41:1035-40
58. Dore GJ, Cooper DA, Pozniak AL, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and-experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004;189:1185-92
59. Peters M, Andersen J, Lynch P, et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 2006;44:1110-6
60. van Bommel F, Wunsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004;40:1421-5
61. Alberti A, Clumeck N, Collins S, et al. Short statement of the first European Consensus Conference on the treatment of chrortic hepatitis B and C in HIV co-infected patients. J Hepatol 2005;42:615-24
62. Dore G, Cooper D, Pozniak AL, et al. Anti-hepatitis B virus activity in HBV/HIV coinfected patients treated with tenofovir DF and lamivudine versus lamivudine alone; 144 week follow-up [abstrac 3308]. XV International AIDS Conference; Bangkok; 2004
63. Stephan C, Berger A, Carlebach A, et al. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus. J Antimicrob Chemother 2005;56:1087-93
64. Marcellin P, Buti M, Kraxtev Z, et al. A randomized, double-blind, comparison of tenofovir DF versus adefovir dipivoxil for the treatment of HBeAg-negative chronic hepatitis B: Study GS-US-174-0102. Hepatology 2007;46:A-LB2
65. Heathcote E, Gane E, DeMan R, et al. A randomized, double-blind, comparison of tenofovir DF versus adefovir dipivoxil for the treatment of HBeAg positive chronic hepatitis B: Study GS-US-174-0103. Hepatology 2007;46:A-LB6
66. Carat F, Bani-Sadr F, Pol S, et al. Pegylated-interferon-alfa-2b plus ribavirin vs standard interferon-alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C in HIV-infected patients. JAMA 2004;292:2839-48
67. Torriani F, Rodriguez-Torres M, Rockstroh J, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351:438-50
68. Soriano V, Puori M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV international panel. AIDS 2007;21:1073-89
69. Pozniak AI, Staszewski S, Gallant JE, et al. Liver transaminase changes in HCV/HIV co-infected patients treated with tenofovir DF versus stavudine in combination with lamivudine and efavirenz [abstract 3307]. XV International AIDS Conference; Bangkok; 2004
70. Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet 2004;43:595-612